Medivir
2.98 SEK +6.43%1 investor is following this company
Medivir is a pharmaceutical company. The company develops drugs and treatments with a focus on cancers and other serious diseases. The company invests in indication areas where available treatment methods are limited or completely lacking research. Collaborations with other partners are part of the business model, and drug development, as well as commercialization, are conducted either in-house or in partnership with other pharmaceutical companies. The head office is located in Huddinge.
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NASDAQ Stockholm
MVIR
Daily low / high price
2.8 / 2.99
SEK
Market cap
341.56M SEK
Turnover
656.19K SEK
Volume
226K
Latest videos
Financial calendar
Interim report
2024-08-22
Interim report
2024-11-06
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Linc AB | 11.3 % | 11.4 % |
HealthInvest Partners AB | 8.3 % | 8.3 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Medivir to present updated clinical data for fostrox + Lenvima in HCC at ESMO Conference in September
Medivir presenterar uppdaterade kliniska data för fostrox + Lenvima vid levercancer (HCC) på ESMO i september
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools